Inozyme Pharma, Inc. (NASDAQ:INZY) Receives $18.33 Consensus Price Target from Analysts

Shares of Inozyme Pharma, Inc. (NASDAQ:INZY - Get Free Report) have been given a consensus recommendation of "Buy" by the nine ratings firms that are presently covering the company, Marketbeat.com reports. Nine equities research analysts have rated the stock with a buy rating. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $18.33.

INZY has been the subject of several analyst reports. Wells Fargo & Company lowered their price objective on Inozyme Pharma from $14.00 to $11.00 and set an "overweight" rating for the company in a research note on Monday, January 13th. Piper Sandler decreased their price target on Inozyme Pharma from $43.00 to $30.00 and set an "overweight" rating for the company in a research note on Monday, January 13th. Wedbush reissued an "outperform" rating and set a $12.00 price target on shares of Inozyme Pharma in a research note on Friday, January 10th. Needham & Company LLC reissued a "buy" rating and set a $23.00 price target on shares of Inozyme Pharma in a research note on Wednesday, November 6th. Finally, HC Wainwright raised their price target on Inozyme Pharma from $14.00 to $16.00 and gave the stock a "buy" rating in a research note on Friday, January 10th.

Institutional Investors Weigh In On Inozyme Pharma

Institutional investors and hedge funds have recently bought and sold shares of the company. abrdn plc bought a new stake in Inozyme Pharma during the 4th quarter valued at $472,000. Eventide Asset Management LLC raised its position in Inozyme Pharma by 5.0% during the 3rd quarter. Eventide Asset Management LLC now owns 4,134,436 shares of the company's stock valued at $21,623,000 after purchasing an additional 198,216 shares in the last quarter. Barclays PLC increased its holdings in shares of Inozyme Pharma by 261.4% in the 3rd quarter. Barclays PLC now owns 76,730 shares of the company's stock valued at $401,000 after acquiring an additional 55,497 shares during the period. Geode Capital Management LLC increased its holdings in shares of Inozyme Pharma by 1.7% in the 3rd quarter. Geode Capital Management LLC now owns 1,171,172 shares of the company's stock valued at $6,126,000 after acquiring an additional 19,499 shares during the period. Finally, State Street Corp increased its holdings in shares of Inozyme Pharma by 5.0% in the 3rd quarter. State Street Corp now owns 1,050,420 shares of the company's stock valued at $5,494,000 after acquiring an additional 50,386 shares during the period. 88.30% of the stock is owned by institutional investors.

Remove Ads

Inozyme Pharma Trading Up 2.8 %

Shares of NASDAQ:INZY traded up $0.03 during trading on Friday, hitting $1.12. The company had a trading volume of 488,528 shares, compared to its average volume of 508,261. The stock has a market cap of $71.95 million, a price-to-earnings ratio of -0.72 and a beta of 1.29. Inozyme Pharma has a one year low of $1.05 and a one year high of $7.80. The company has a fifty day simple moving average of $1.77 and a two-hundred day simple moving average of $3.46. The company has a debt-to-equity ratio of 0.51, a current ratio of 7.68 and a quick ratio of 7.68.

About Inozyme Pharma

Inozyme Pharma, Inc, a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis.